Related Experiment Video
Updated: Jul 3, 2026
07:53
Visualization and Quantitative Analysis of Genotoxin-Induced PARP1/PARP2 Activation in Cells Using a Fluorescent Fusion Protein-Based Reporter
Published on: April 17, 2026
Decoding PARP roles in breast cancer therapy resistance.
Mohammad Abohassan1, Farag M Altalbawy2, Majid S Jabir3
1Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
Molecular Biology Reports
|July 2, 2026
Summary
Poly(ADP-ribose) polymerase (PARP) inhibitors show promise for breast cancer, but resistance limits effectiveness. Understanding resistance mechanisms and combining therapies can improve patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Poly(ADP-ribose) polymerase (PARP) inhibitors are effective in treating breast cancers with homologous recombination deficiency, such as BRCA1/2-mutated tumors.
- Intrinsic and acquired resistance to PARP inhibitors limit their long-term clinical utility in breast cancer treatment.
Purpose of the Study:
- To review the biological functions of PARPs.
- To synthesize evidence on molecular mechanisms of resistance to PARP inhibition in breast cancer.
- To explore interactions between PARP signaling and other therapeutic pathways.
Main Methods:
- Literature review of existing evidence on PARP inhibitors in breast cancer.
- Analysis of molecular mechanisms underlying resistance to PARP inhibition.
- Examination of signaling pathway interactions and therapeutic strategies.
Main Results:
- Major resistance mechanisms include restoration of homologous recombination, loss of 53BP1, replication fork stabilization, increased drug efflux, loss of PARG, and epigenetic alterations.
- PARP signaling interacts with endocrine, HER2-targeted, and PI3K/AKT pathways, influencing the tumor microenvironment and immune evasion.
- Next-generation PARP1-selective inhibitors and combination therapies are emerging strategies to overcome resistance.
Conclusions:
- Combining mechanistic insights with clinical innovation is crucial for patient selection and sustainable therapy.
- Biomarker-guided approaches and combination therapies are vital for enhancing PARP inhibitor efficacy in breast cancer.
- Further research is needed to fully overcome resistance and improve treatment outcomes for breast cancer patients.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:02Long-patch Base Excision Repair
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
02:37Restarting Stalled Replication Forks
DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart, a...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...